[1] GUAN T，MA J，LI M，et al. Rapid transitions in

the epidemiology of stroke and its risk factors in

China from 2002 to 2013[J]. Neurology，2017，89（1）：

53-61.

[2] ZHOU M，WANG H，ZHU J，et al. Cause-specific

mortality for 240 causes in China during 1990-2013：

a systematic subnational analysis for the global

burden of disease study 2013[J]. Lancet，2016，387

（10 015）：251-272.

[3] WANG W，JIANG B，SUN H，et al. Prevalence，

incidence，and mortality of stroke in China：results

from a nationwide population-based survey of 480

687 adults[J]. Circulation，2017，135（8）：759-771.

[4] WANG Y，LI Z，ZHAO X，et al. Effect of a

multifaceted quality improvement intervention

on hospital personnel adherence to performance

measures in patients with acute ischemic stroke in

China：a randomized clinical trial[J]. JAMA，2018，

320（3）：245-254.

[5] AMARENCO P，BOGOUSSLAVSKY J，

CALLAHAN A，et al. High-dose atorvastatin after

stroke or transient ischemic attack[J]. N Engl J Med，

2006，355（6）：549-559.

[6] AMARENCO P，GOLDSTEIN L B，SZAREK

M，et al. Effects of intense low-density lipoprotein

cholesterol reduction in patients with stroke or

transient ischemic attack：the stroke prevention by

aggressive reduction in cholesterol levels（sparcl）

trial[J]. Stroke，2007，38（12）：3198-3204.

[7] CHIMOWITZ M I，LYNN M J，DERDEYN C P，et al. Stenting versus aggressive medical therapy for

intracranial arterial stenosis[J]. N Engl J Med，2011，

365（11）：993-1003.

[8] DERDEYN C P，CHIMOWITZ M I，LYNN M J，et

al. Aggressive medical treatment with or without

stenting in high-risk patients with intracranial

artery stenosis（sammpris）：the final results of a

randomised trial[J]. Lancet，2014，383（9914）：333-

341.

[9] WANG Y，LIU M，PU C. 2014 chinese guidelines

for secondary prevention of ischemic stroke and

transient ischemic attack[J]. Int J Stroke，2017，12

（3）：302-320.

[10] WANG C J，WANG Y L，LI Z X，et al. The

management of ldl cholesterol and predictors of goal

achievement in stroke patients in China：a crosssectional

study[J]. CNS Neurosci Ther，2016，22（7）：

577-583.

[11] SEIDAH N G，AWAN Z，CHRETIEN M，et al.

Pcsk9：a key modulator of cardiovascular health[J].

Circ Res，2014，114（6）：1022-1036.

[12] SABATINE M S，GIUGLIANO R P，KEECH A C，

et al. Evolocumab and clinical outcomes in patients

with cardiovascular disease[J]. N Engl J Med，2017，

376（18）：1713-1722.

[13] SCHWARTZ G G，STEG P G，SZAREK M，et al.

Alirocumab and cardiovascular outcomes after acute

coronary syndrome[J]. N Engl J Med，2018，379

（22）：2097-2107.

[14] 中国卒中学会. 急性缺血性卒中血管内治疗中国指南

2018[J]. 中国卒中杂志，2018，13（7）：706-729.

[15] ZHANG X L，ZHU Q Q，ZHU L，et al. Safety and

efficacy of anti-pcsk9 antibodies：a meta-analysis of

25 randomized，controlled trials[J/OL]. BMC Med，

2015，13：123. https：//doi.org/10.1186/s12916-015-

0358-8.

[16] TOTH P P，WORTHY G，GANDRA S R，et al.

Systematic review and network meta-analysis on the

efficacy of evolocumab and other therapies for the

management of lipid levels in hyperlipidemia[J/OL].

J Am Heart Assoc，2017，6（10）. pii：e005367. https：

//doi.org/10.1161/JAHA.116.005367.

[17] KOREN M J，SABATINE M S，GIUGLIANO R P，

et al. Long-term low-density lipoprotein cholesterollowering

efficacy，persistence，and safety of

evolocumab in treatment of hypercholesterolemia：

Results up to 4 years from the open-label osler-1

extension study[J]. JAMA Cardiol，2017，2（6）：

598-607.

[18] GIUGLIANO R P，SABATINE M S，OTT B

R. Cognitive function in a randomized trial of

evolocumab[J]. N Engl J Med，2017，377（20）：

1996-1997.

[19] TOTH P P，DESCAMPS O，GENEST J，et al.

Pooled safety analysis of evolocumab in over 6000

patients from double-blind and open-label extension

studies[J]. Circulation，2017，135（19）：1819-1831.

[20] JONES P H，BAYS H E，CHAUDHARI U，et al.

Safety of alirocumab（a pcsk9 monoclonal antibody）

from 14 randomized trials[J]. Am J Cardiol，2016，

118（12）：1805-1811.

[21] KOREN M J，SABATINE M S，GIUGLIANO

R P，et al. Final report of the osler-1 study：

long-term evolocumab for the treatment of

hypercholesterolemia[J/OL]. Circulation，2018，138

（suppl1）：A14154. https：//www.ahajournals.org/

doi/10.1161/circ.138.suppl_1.14154.

[22] PEDERSEN T，GIUGLIANO R，SEVER P，et

al. Further cardiovascular outcomes research with

pcsk9 inhibition in subjects with elevated risk（focus

on cerebrovascular disease）[EB/OL]. （2019-03-

12）[2017-12-15]. https：//clinicaltrials.gov/ct2/show/

results/NCT01764633.

[23] DU H，LI X，SU N，et al. Proprotein convertase

subtilisin/kexin 9 inhibitors in reducing

cardiovascular outcomes：a systematic review

and meta-analysis[J/OL]. Heart，2019，pii：

heartjnl-2019-314763. https：//doi.org/10.1136/

heartjnl-2019-314763.

[24] GRUNDY S M，STONE N J，BAILEY A L，et

al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/

ADA/AGS/APHA/ASPC/NLA/PCNA guideline

on the management of blood cholesterol：a report

of the American College of Cardiology/American

Heart Association task force on clinical practice

guidelines[J/OL]. J Am Coll Cardiol，2018，pii：

S0735-1097（18）39035-1. https：//doi.org/10.1016/j.

jacc.2018.11.004.

[25] LANDMESSER U，CHAPMAN M J，STOCK J

K，et al. 2017 update of ESC/EAS task force on

practical clinical guidance for proprotein convertase

subtilisin/kexin type 9 inhibition in patients with

atherosclerotic cardiovascular disease or in familial

hypercholesterolaemia[J/OL]. Eur Heart J，2018，39：

1131-1143. https：//doi.org/10.1093/eurheartj/ehx648.

[26] 中华医学会心血管病学分会动脉粥样硬化及冠心病

学组. 家族性高胆固醇血症筛查与诊治中国专家共

识[J]. 中华心血管病杂志，2018，46（2）：99-103.